Locations:
Search IconSearch
July 14, 2017/Cancer

Well-Differentiated Lipomatous Tumors: A Case Series (Video)

Soft tissue pathology service’s most common consult

In this case series, John Goldblum, MD, chairman of the Department of Pathology in Cleveland Clinic’s Robert J. Tomsich’s Pathology and Laboratory Medicine Institute and an expert in soft tissue tumor pathology, reviews three cases of soft tissue tumors. According to Dr. Goldblum, well-differentiated lipomatous tumors are the most common reason that clinicians consult the department’s soft tissue pathology service. “It’s a very common problem seen by all surgical pathologists,” he says, before offering an overview of Cleveland Clinic’s approach to identifying these legions through the lens of three typical cases.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

He illustrates how to distinguish among pleomorphic lipomas, well-differentiated liposarcomas (also known as atypical lipomatous tumors) and dedifferentiated liposarcomas. The first case is a 49-year-old male with an upper back mass, and Dr. Goldblum emphasizes that the multi-nucleated floret-like giant cells seen in the slide are suggestive of but not pathognomonic of pleomorphic lipomas.

The second case is a deep soft tissue mass from the thigh of a 65-year-old female. Dr. Goldblum notes the atypical hyperchromatic nuclei that lead him toward a diagnosis of well-differentiated liposarcoma. He also explains why he never looks for lipoblasts when examining a well-differentiated fatty tumor.

In this case series, John Goldblum, MD, chairman of the Department of Pathology in Cleveland Clinic’s Robert J. Tomsich’s Pathology and Laboratory Medicine Institute and an expert in soft tissue tumor pathology, reviews three cases of soft tissue tumors. According to Dr. Goldblum, well-differentiated lipomatous tumors are the most common reason that clinicians consult the department’s soft tissue pathology service. “It’s a very common problem seen by all surgical pathologists,” he says, before offering an overview of Cleveland Clinic’s approach to identifying these legions through the lens of three typical cases.

He illustrates how to distinguish among pleomorphic lipomas, well-differentiated liposarcomas (also known as atypical lipomatous tumors) and dedifferentiated liposarcomas. The first case is a 49-year-old male with an upper back mass, and Dr. Goldblum emphasizes that the multi-nucleated floret-like giant cells seen in the slide are suggestive of but not pathognomonic of pleomorphic lipomas.

Advertisement

The second case is a deep soft tissue mass from the thigh of a 65-year-old female. Dr. Goldblum notes the atypical hyperchromatic nuclei that lead him toward a diagnosis of well-differentiated liposarcoma. He also explains why he never bothers to identify lipoblasts when examining a well-differentiated fatty tumor.

In the final case, he examines a large retroperitoneal mass from an elderly patient and highlights the importance of examining the slide’s periphery in order to identify any well-differentiated liposarcomatous components. Find out why Dr. Goldblum argues that the type of spindle cell sarcoma is inconsequential in this case in the video below:

Pathology Insights: Well-Differentiated Lipomatous Tumors with John Goldblum, MD

The accurate diagnosis, grading and staging of benign and malignant soft tissue neoplasms, as well as mesenchymal neoplasms of the skin and parenchymal organs, can be challenging. Cleveland Clinic’s soft tissue pathology service, led by Karen Fritchie, MD, offers consultations on some of the most difficult cases in soft tissue pathology as well as a fellowship program and continuing medical education opportunities for practicing pathologists.

Advertisement

Related Articles

Cancer patient being hugged by a loved one
September 4, 2024/Cancer/Blood Cancers
Study Finds Immunotherapy Increases Three-Year Survival in Adults with B-Cell Precursor Acute Lymphoblastic Leukemia

Blinatumomab plus chemotherapy improves overall survival and relapse-free survival over chemotherapy alone

Doctor and team talking to patient in hospital bed
August 30, 2024/Cancer/Patient Support
New Cellular and Immunotherapy Service Provides Patients with Standard of Care and Clinical Trial Opportunities for Novel Therapies

Patients receive specialized inpatient and outpatient care for cellular, gene and immune cell-engaging therapies

Before and after scan
August 28, 2024/Cancer/Research
Case Study: Patient with Metastatic Urothelial Carcinoma Has No Remaining Evidence of Disease

Treatment involved checkpoint inhibitor, surgery and intravesical therapy

Dr. Maciejewski
August 23, 2024/Cancer/Research
Studies Evaluate Anti-Complement Inhibitors for Treating Paroxysmal Nocturnal Hemoglobinuria

Researchers Assess Real-Life Experiences of Patients Treated Outside of Clinical Trials

Dr. Raza
August 19, 2024/Cancer/Research
Understanding the Role of Palliative Care in AL Amyloidosis

Multi-specialty coordination essential for improving quality of life

Dr. Chirag Shah and colleague
August 12, 2024/Cancer/Research
DCISionRT Decision Score Predicts the Need of Radiation Therapy for Treating Ductal Carcinoma in Situ

Seven-gene biosignature becomes first effective means to reduce over- and under-treatment with radiation therapy

Diffuse large B-cell lymphoma
August 1, 2024/Cancer/Research
Emerging Second- and Third-Line Treatments Improve Outcomes in Diffuse Large B-Cell Lymphoma

CAR T-cell therapy, bispecifics and antibody drug conjugates have changed disease management

Ad